Form 8-K - Current report:
SEC Accession No. 0000950170-22-016467
Filing Date
2022-08-10
Accepted
2022-08-10 16:11:11
Documents
13
Period of Report
2022-08-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sprb-20220810.htm   iXBRL 8-K 60658
2 EX-99.1 sprb-ex99_1.htm EX-99.1 319323
  Complete submission text file 0000950170-22-016467.txt   523825

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT sprb-20220810_pre.xml EX-101.PRE 11620
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT sprb-20220810_lab.xml EX-101.LAB 18598
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT sprb-20220810.xsd EX-101.SCH 2527
7 EXTRACTED XBRL INSTANCE DOCUMENT sprb-20220810_htm.xml XML 4901
Mailing Address 2001 JUNIPERO SERRA BLVD., SUITE 640 DALY CITY CA 94104
Business Address 2001 JUNIPERO SERRA BLVD., SUITE 640 DALY CITY CA 94104 (415) 294-1687
SPRUCE BIOSCIENCES, INC. (Filer) CIK: 0001683553 (see all company filings)

EIN.: 812154263 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39594 | Film No.: 221151939
SIC: 2834 Pharmaceutical Preparations